盐酸缬更昔洛韦片治疗CMV视网膜炎效果好吗？

It is a new antiviral drug and a prodrug of ganciclovir. It is mainly used to treat acute retinitis caused by cytomegalovirus (CMV) infection in HIV-infected patients (AIDS patients) and to prevent CMV infection in high-risk solid organ transplant patients. The oral bioavailability of valganciclovir is much higher than that of ganciclovir, and its toxicity is greatly reduced. The drug is currently on the market in China and has broad market prospects.

Is Valganciclovir Hydrochloride Tablets effective in treating CMV retinitis?

Clinical studies of Valcyte in AIDS patients infected with CMV retinitis have shown that valganciclovir hydrochloride tablets and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the Valcyte group or the intravenous ganciclovir group for induction therapy. The proportion of patients with progression of CMV retinitis at week 4 was the same in both groups. After induction therapy, both groups of patients in the study continued to receive maintenance therapy with Valcyte 900 mg daily. Among patients who received induction therapy with Valcyte or intravenous ganciclovir followed by maintenance therapy, the mean (median) time from randomization to progression of CMV retinitis was: 226 (160) days and 219 (125) days. Common adverse reactions in the study include: gastrointestinal disorders: abdominal distension, cholangitis, dyspepsia, dysphagia, hiccups, esophagitis, fecal incontinence, flatulence, gastritis, gastrointestinal disorders, gastrointestinal bleeding, oral ulcers, pancreatitis, and tongue dysfunction. Systemic: ascites, asthenia, bacterial, fungal and viral infections, bleeding, malaise, mucosal disease, pain, photosensitivity, chills, sepsis. Liver disorders: hepatitis, jaundice. Skin and appendages: Acne, alopecia, seborrheic dermatitis, dry skin, increased sweating, urticaria.